Genetron Holdings Ltd. ADR (GTH): Price and Financial Metrics
GET POWR RATINGS... FREE!
GTH POWR Grades
- Sentiment is the dimension where GTH ranks best; there it ranks ahead of 90.51% of US stocks.
- The strongest trend for GTH is in Stability, which has been heading down over the past 31 weeks.
- GTH's current lowest rank is in the Quality metric (where it is better than 4.73% of US stocks).
GTH Stock Summary
- Genetron Holdings Ltd's stock had its IPO on June 19, 2020, making it an older stock than only 0.58% of US equities in our set.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -29.65 for Genetron Holdings Ltd; that's greater than it is for only 0.81% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for GTH comes in at -95.98% -- higher than that of just 2.32% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Genetron Holdings Ltd are SESN, VVV, LEE, HZN, and FLXN.
- To dig deeper into the stock's financial statements, go to GTH's page on browse-edgar?action=getcompany&CIK=0001782594.
GTH Stock Price Chart Interactive Chart >
GTH Price/Volume Stats
| Current price | $20.64 | 52-week high | $31.54 |
| Prev. close | $19.88 | 52-week low | $9.03 |
| Day low | $19.71 | Volume | 153,569 |
| Day high | $20.80 | Avg. volume | 364,960 |
| 50-day MA | $20.26 | Dividend yield | N/A |
| 200-day MA | $17.58 | Market Cap | 1.83B |
Genetron Holdings Ltd. ADR (GTH) Company Bio
Genetron Holdings, Ltd. engages in precision oncology. It provides cancer molecular profiling by using technologies in molecular biology and data science to transform cancer treatment. It products and services include diagnosis and monitoring through both LDT and IVD products. Its LDT portfolio consists of both specifically designed focused and comprehensive gene panel testing services. It also develops liver cancer early screening products. The company was founded by Si Zhen Wang, Hai Yan, and Wei Wu He in 2015 and is headquartered in Beijing, China.
Latest GTH News From Around the Web
Below are the latest news stories about Genetron Holdings Ltd that investors may wish to consider to help them evaluate GTH as an investment opportunity.
Genetron Health Releases 16 New Research Results at 2021 American Society of Clinical Oncology (ASCO) Annual MeetingBEIJING, June 04, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced the release of 16 research results at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The results were from studies that Genetron Health conducted in partnershi |
Genetron Holdings Limited 2021 Q1 - Results - Earnings Call PresentationThe following slide deck was published by Genetron Holdings Limited in conjunction with their 2021 Q1 earnings call.... |
Genetron Health Announces Strategic Partnership with Siemens Healthineers to Promote Precision Oncology for Lung CancerGenetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced a strategic partnership with Siemens Healthineers at the China Medical Equipment Fair. |
Genetron Health Releases 22 New Research Results at American Association for Cancer Research Annual Meeting (AACR) 2021Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced the release of 22 research results at the American Association for Cancer Research Annual Meeting 2021 (AACR 2021). |
Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx SummitBEIJING, April 01, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit on Wednesday April 7th, 2021. Interested parties may request more information by contacting their sales representative at SVB Leerink. About Genetron Holdings LimitedGenetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologi... |
GTH Price Returns
| 1-mo | 6.34% |
| 3-mo | -10.34% |
| 6-mo | 54.49% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 47.43% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...